Clinical Trial Update: Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of CLR-131 in children with relapsed or refractory malignant tumors, including neuroblastoma and sarcomas, currently listed as act…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Intrinsic Pontine Glioma
• Ewing Sarcoma
• Neuroblastoma
• Osteosarcoma
• Rhabdomyosarcoma

Drugs mentioned

• CLR 131

Snippet

Sponsor: Cellectar Biosciences, Inc. | Conditions: Pediatric Solid Tumor, Pediatric Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING